X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
lbh589 (147) 147
humans (138) 138
index medicus (138) 138
oncology (98) 98
panobinostat (85) 85
hematology (54) 54
histone deacetylase inhibitors - pharmacology (54) 54
apoptosis (53) 53
histone deacetylase inhibitors (52) 52
hydroxamic acids - pharmacology (52) 52
cancer (51) 51
female (49) 49
animals (48) 48
bortezomib (42) 42
histone deacetylase inhibitor (42) 42
cell line, tumor (39) 39
male (39) 39
hydroxamic acids - administration & dosage (36) 36
middle aged (36) 36
antineoplastic agents - pharmacology (34) 34
multiple myeloma (34) 34
apoptosis - drug effects (33) 33
histone deacetylase inhibitors - therapeutic use (33) 33
indoles (33) 33
aged (32) 32
multiple myeloma - drug therapy (32) 32
antineoplastic agents - therapeutic use (31) 31
cell proliferation - drug effects (31) 31
hydroxamic acids - therapeutic use (31) 31
mice (29) 29
pharmacology & pharmacy (29) 29
care and treatment (28) 28
indoles - pharmacology (28) 28
suberoylanilide hydroxamic acid (28) 28
treatment outcome (28) 28
adult (27) 27
combination (27) 27
histone deacetylase (27) 27
expression (26) 26
hydroxamic acids - adverse effects (26) 26
research (26) 26
vorinostat (25) 25
article (24) 24
histone deacetylases - metabolism (24) 24
indoles - administration & dosage (24) 24
acetylation (23) 23
tumors (23) 23
histone deacetylase inhibitors - administration & dosage (21) 21
indoles - therapeutic use (21) 21
panobinostat lbh589 (21) 21
drug therapy (20) 20
antineoplastic combined chemotherapy protocols - therapeutic use (19) 19
hdac inhibitors (19) 19
indoles - adverse effects (19) 19
medicine & public health (19) 19
phase-i (19) 19
proteins (19) 19
gene expression (18) 18
hematology, oncology and palliative medicine (18) 18
histone deacetylase inhibitors - adverse effects (18) 18
neoplasms - drug therapy (18) 18
analysis (17) 17
dexamethasone (17) 17
drug synergism (17) 17
histones - metabolism (17) 17
therapy (17) 17
cell cycle (16) 16
cells (16) 16
hdac inhibitor (16) 16
multiple myeloma - pathology (16) 16
survival (16) 16
antineoplastic agents - administration & dosage (15) 15
dose-response relationship, drug (15) 15
multicenter (15) 15
epigenetics (14) 14
gene-expression (14) 14
clinical trials (13) 13
hdac (13) 13
hydroxamic acids - pharmacokinetics (13) 13
xenograft model antitumor assays (13) 13
administration, oral (12) 12
aged, 80 and over (12) 12
antineoplastic agents - adverse effects (12) 12
biochemistry & molecular biology (12) 12
chemotherapy (12) 12
growth (12) 12
leukemia (12) 12
lymphomas (12) 12
pharmacology/toxicology (12) 12
recurrence (12) 12
valproic acid (12) 12
antineoplastic combined chemotherapy protocols - pharmacology (11) 11
breast cancer (11) 11
clinical trials as topic (11) 11
drug administration schedule (11) 11
histone deacetylases (11) 11
histones (11) 11
in-vitro (11) 11
induction (11) 11
medical colleges (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, ISSN 0390-6078, 05/2010, Volume 95, Issue 5, pp. 794 - 803
Background Combinations of drug treatments based on bortezomib or lenalidomide plus steroids have resulted in very high response rates in multiple myeloma.... 
SURVIVAL | BONE-DISEASE | multiple myeloma | EXTRAMEDULLARY RELAPSES | HDAC inhibitors | panobinostat | HISTONE ACETYLATION | CANCER | CHEMOTHERAPY | TRANSPLANTATION | PLUS DEXAMETHASONE | LBH589 | THERAPIES | INHIBITOR LBH589 | HEMATOLOGY
Journal Article
OncoTargets and Therapy, ISSN 1178-6930, 05/2016, Volume 2016, Issue Issue 1, pp. 2783 - 2793
Kimberly A Redic,1 Shannon M Hough,2 Erika M Price11College of Pharmacy, University of Michigan, 2Department of Pharmaceutical Services, University of Michigan... 
Panobinostat | LBH589 | Multiple Myeloma
Journal Article
Molecular Cancer Research, ISSN 1541-7786, 10/2018, Volume 16, Issue 10, pp. 1530 - 1542
Aromatase, a cytochrome P450 member, is a key enzyme involved in estrogen biosynthesis and is dysregulated in the majority of breast cancers. Studies have... 
THERAPY | ONCOLOGY | BREAST-CANCER RISK | DISEASE | LBH589 | ENDOMETRIAL | PROLIFERATION | PANOBINOSTAT | EXPRESSION | ESTROGEN-RECEPTOR | VORINOSTAT | CELL BIOLOGY
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1195 - 1206
Journal Article
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 02/2019, Volume 509, Issue 2, pp. 476 - 482
Dysregulation of steroid biosynthesis has been implicated in the pathophysiology of a variety of cancers. One such common malignancy in women is breast cancer... 
HDAC inhibition | Breast cancer | Acetylation | Steroid biosynthesis | StAR | Estrogen | BIOPHYSICS | BIOCHEMISTRY & MOLECULAR BIOLOGY | LBH589 | AROMATASE | MOLECULAR-MECHANISMS
Journal Article
Journal Article
Oncotarget, ISSN 1949-2553, 06/2018, Volume 9, Issue 47, pp. 28586 - 28598
Non-Hodgkin lymphoma (NHL) is one of the most common causes of cancer-related death in the United States and Europe. Although the outcome of NHL patients has... 
Non-Hodgkin lymphoma | Panobinostat | HDAC inhibitors | Canine lymphoma | LBH589
Journal Article
Blood, ISSN 0006-4971, 03/2012, Volume 119, Issue 11, pp. 2579 - 2589
Journal Article
CANCER CHEMOTHERAPY AND PHARMACOLOGY, ISSN 0344-5704, 10/2012, Volume 70, Issue 4, pp. 513 - 522
Elucidating the metabolic profile of anticancer agent panobinostat is essential during drug development. Disposition, metabolism, and excretion profiles were... 
Panobinostat | Excretion | SOLID TUMORS | ONCOLOGY | LBH589 | Disposition | LYMPHOMA | PHARMACOLOGY & PHARMACY | Metabolism | DACi
Journal Article
OncoTargets and Therapy, ISSN 1178-6930, 2013, Volume 6, pp. 1613 - 1624
The histone deacetylase (HDAC) inhibitors have emerged as novel therapies for cancer. Panobinostat (LBH 589, Novartis Pharmaceuticals) is a pan-deacetylase... 
Panobinostat | Histone deacetylase inhibitor | Solid tumors | LBH589 | OVARIAN-CANCER | COMBINATION | panobinostat | solid tumors | CELL-DEATH | LUNG-CANCER | HEPATOCELLULAR-CARCINOMA | ONCOLOGY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | histone deacetylase inhibitor | DAC INHIBITOR | SUPERIOR EFFICACY | LBH589 INCREASES | PHASE-I | Tumors | Apoptosis
Journal Article
Current Topics in Medicinal Chemistry, ISSN 1568-0266, 11/2016, Volume 16, Issue 4, pp. 427 - 434
Histone acetyl transferases (HATs) and histone deacetylases (HDACs) are antagonistic enzymes regulating the turnover of histone acetylation thereby governing... 
Panobinostat | Histone deacetylase inhibitors | Histone deacetylases | Metalloenzymes | Multiple myeloma | Cancer | CANCER-CELLS | TARGET | HISTONE DEACETYLASE INHIBITOR | CHEMISTRY, MEDICINAL | OVARIAN-CANCER | AUTOPHAGY | LUNG-CANCER | IN-VITRO | PROSTATE-CANCER | LBH589 | HDAC
Journal Article